Literature DB >> 23047742

Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Shay Ben-Shachar1, Shlomi Constantini, Hen Hallevi, Emma K Sach, Meena Upadhyaya, Gareth D Evans, Susan M Huson.   

Abstract

Neurofibromatosis type 1 (NF1) and its related disorders (NF1-Noonan syndrome (NFNS) and Watson syndrome (WS)) are caused by heterozygous mutations in the NF1 gene. Pulmonary stenosis (PS) occurs more commonly in NF1 and its related disorders than in the general population. This study investigated whether PS is associated with specific types of NF1 gene mutations in NF1, NFNS and WS. The frequency of different NF1 mutation types in a cohort of published and unpublished cases with NF1/NFNS/WS and PS was examined. Compared with NF1 in general, NFNS patients had higher rates of PS (9/35=26% vs 25/2322=1.1%, P value<0.001). Stratification according to mutation type showed that the increased PS rate appears to be driven by the NFNS group with non-truncating mutations. Eight of twelve (66.7%) NFNS cases with non-truncating mutations had PS compared with a 1.1% PS frequency in NF1 in general (P<0.001); there was no increase in the frequency of PS in NFNS patients with truncating mutations. Eight out of eleven (73%) individuals with NF1 and PS, were found to have non-truncating mutations, a much higher frequency than the 19% reported in NF1 cohorts (P<0.015). Only three cases of WS have been published with intragenic mutations, two of three had non-truncating mutations. Therefore, PS in NF1 and its related disorders is clearly associated with non-truncating mutations in the NF1 gene providing a new genotype-phenotype correlation. The data indicate a specific role of non-truncating mutations on the NF1 cardiac phenotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23047742      PMCID: PMC3641387          DOI: 10.1038/ejhg.2012.221

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  28 in total

1.  Evaluation of genotype-phenotype correlations in neurofibromatosis type 1.

Authors:  B Castle; M E Baser; S M Huson; D N Cooper; M Upadhyaya
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

2.  Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.

Authors:  Laura Thomas; Mark Richards; Matthew Mort; Elaine Dunlop; David N Cooper; Meena Upadhyaya
Journal:  Hum Mutat       Date:  2012-08-06       Impact factor: 4.878

3.  Pulmonary stenosis, café-au-lait spots, and dull intelligence.

Authors:  G H Watson
Journal:  Arch Dis Child       Date:  1967-06       Impact factor: 3.791

4.  Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis.

Authors:  A Colley; D Donnai; D G Evans
Journal:  Clin Genet       Date:  1996-02       Impact factor: 4.438

5.  Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS).

Authors:  Diana Baralle; Chris Mattocks; Kamini Kalidas; Frances Elmslie; Joanne Whittaker; Melissa Lees; Nicola Ragge; Michael A Patton; Robin M Winter; Charles ffrench-Constant
Journal:  Am J Med Genet A       Date:  2003-05-15       Impact factor: 2.802

6.  Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1.

Authors:  A E Lin; P H Birch; B R Korf; R Tenconi; M Niimura; M Poyhonen; K Armfield Uhas; M Sigorini; R Virdis; C Romano; E Bonioli; P Wolkenstein; E K Pivnick; M Lawrence; J M Friedman
Journal:  Am J Med Genet       Date:  2000-11-13

7.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

Authors:  L M Messiaen; T Callens; G Mortier; D Beysen; I Vandenbroucke; N Van Roy; F Speleman; A D Paepe
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  Watson syndrome: is it a subtype of type 1 neurofibromatosis?

Authors:  J E Allanson; M Upadhyaya; G H Watson; M Partington; A MacKenzie; D Lahey; H MacLeod; M Sarfarazi; W Broadhead; P S Harper
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

9.  Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome.

Authors:  M Tassabehji; T Strachan; M Sharland; A Colley; D Donnai; R Harris; N Thakker
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

10.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene.

Authors:  Lan Kluwe; Reiner Siebert; Stefan Gesk; Reinhard E Friedrich; Sigrid Tinschert; Hildegard Kehrer-Sawatzki; Victor-F Mautner
Journal:  Hum Mutat       Date:  2004-02       Impact factor: 4.878

View more
  11 in total

1.  High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation.

Authors:  Kitiwan Rojnueangnit; Jing Xie; Alicia Gomes; Angela Sharp; Tom Callens; Yunjia Chen; Ying Liu; Meagan Cochran; Mary-Alice Abbott; Joan Atkin; Dusica Babovic-Vuksanovic; Christopher P Barnett; Melissa Crenshaw; Dennis W Bartholomew; Lina Basel; Gary Bellus; Shay Ben-Shachar; Martin G Bialer; David Bick; Bruce Blumberg; Fanny Cortes; Karen L David; Anne Destree; Anna Duat-Rodriguez; Dawn Earl; Luis Escobar; Marthanda Eswara; Begona Ezquieta; Ian M Frayling; Moshe Frydman; Kathy Gardner; Karen W Gripp; Concepcion Hernández-Chico; Kurt Heyrman; Jennifer Ibrahim; Sandra Janssens; Beth A Keena; Isabel Llano-Rivas; Kathy Leppig; Marie McDonald; Vinod K Misra; Jennifer Mulbury; Vinodh Narayanan; Naama Orenstein; Patricia Galvin-Parton; Helio Pedro; Eniko K Pivnick; Cynthia M Powell; Linda Randolph; Salmo Raskin; Jordi Rosell; Karol Rubin; Margretta Seashore; Christian P Schaaf; Angela Scheuerle; Meredith Schultz; Elizabeth Schorry; Rhonda Schnur; Elizabeth Siqveland; Amanda Tkachuk; James Tonsgard; Meena Upadhyaya; Ishwar C Verma; Stephanie Wallace; Charles Williams; Elaine Zackai; Jonathan Zonana; Conxi Lazaro; Kathleen Claes; Bruce Korf; Yolanda Martin; Eric Legius; Ludwine Messiaen
Journal:  Hum Mutat       Date:  2015-08-21       Impact factor: 4.878

2.  Prevalence, Type, and Molecular Spectrum of NF1 Mutations in Patients with Neurofibromatosis Type 1 and Congenital Heart Disease.

Authors:  Valentina Pinna; Paola Daniele; Giulio Calcagni; Lucio Mariniello; Roberta Criscione; Chiara Giardina; Francesca Romana Lepri; Hossein Hozhabri; Angela Alberico; Stefania Cavone; Annunziata Tina Morella; Roberta Mandile; Francesca Annunziata; Niccolò Di Giosaffatte; Maria Cecilia D'Asdia; Paolo Versacci; Rossella Capolino; Pietro Strisciuglio; Sandra Giustini; Daniela Melis; Maria Cristina Digilio; Marco Tartaglia; Bruno Marino; Alessandro De Luca
Journal:  Genes (Basel)       Date:  2019-09-04       Impact factor: 4.096

3.  The Arg1038Gly missense variant in the NF1 gene causes a mild phenotype without neurofibromas.

Authors:  Eva Trevisson; Valeria Morbidoni; Monica Forzan; Cecilia Daolio; Valentina Fumini; Raffaele Parrozzani; Matteo Cassina; Edoardo Midena; Leonardo Salviati; Maurizio Clementi
Journal:  Mol Genet Genomic Med       Date:  2019-03-06       Impact factor: 2.183

4.  Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1.

Authors:  Magdalena Koczkowska; Tom Callens; Yunjia Chen; Alicia Gomes; Alesha D Hicks; Angela Sharp; Eric Johns; Kim Armfield Uhas; Linlea Armstrong; Katherine Armstrong Bosanko; Dusica Babovic-Vuksanovic; Laura Baker; Donald G Basel; Mario Bengala; James T Bennett; Chelsea Chambers; Lola K Clarkson; Maurizio Clementi; Fanny M Cortés; Mitch Cunningham; M Daniela D'Agostino; Martin B Delatycki; Maria C Digilio; Laura Dosa; Silvia Esposito; Stephanie Fox; Mary-Louise Freckmann; Christine Fauth; Teresa Giugliano; Sandra Giustini; Allison Goetsch; Yael Goldberg; Robert S Greenwood; Cristin Griffis; Karen W Gripp; Punita Gupta; Eric Haan; Rachel K Hachen; Tamara L Haygarth; Concepción Hernández-Chico; Katelyn Hodge; Robert J Hopkin; Louanne Hudgins; Sandra Janssens; Kory Keller; Geraldine Kelly-Mancuso; Aaina Kochhar; Bruce R Korf; Andrea M Lewis; Jan Liebelt; Angie Lichty; Robert H Listernick; Michael J Lyons; Isabelle Maystadt; Mayra Martinez Ojeda; Carey McDougall; Lesley K McGregor; Daniela Melis; Nancy Mendelsohn; Malgorzata J M Nowaczyk; June Ortenberg; Karin Panzer; John G Pappas; Mary Ella Pierpont; Giulio Piluso; Valentina Pinna; Eniko K Pivnick; Dinel A Pond; Cynthia M Powell; Caleb Rogers; Noa Ruhrman Shahar; S Lane Rutledge; Veronica Saletti; Sarah A Sandaradura; Claudia Santoro; Ulrich A Schatz; Allison Schreiber; Daryl A Scott; Elizabeth A Sellars; Ruth Sheffer; Elizabeth Siqveland; John M Slopis; Rosemarie Smith; Alberto Spalice; David W Stockton; Haley Streff; Amy Theos; Gail E Tomlinson; Grace Tran; Pamela L Trapane; Eva Trevisson; Nicole J Ullrich; Jenneke Van den Ende; Samantha A Schrier Vergano; Stephanie E Wallace; Michael F Wangler; David D Weaver; Kaleb H Yohay; Elaine Zackai; Jonathan Zonana; Vickie Zurcher; Kathleen B M Claes; Marica Eoli; Yolanda Martin; Katharina Wimmer; Alessandro De Luca; Eric Legius; Ludwine M Messiaen
Journal:  Hum Mutat       Date:  2019-10-26       Impact factor: 4.878

5.  Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort.

Authors:  Giulia Melloni; Marica Eoli; Claudia Cesaretti; Donatella Bianchessi; Maria Cristina Ibba; Silvia Esposito; Giulietta Scuvera; Guido Morcaldi; Roberto Micheli; Elena Piozzi; Sabrina Avignone; Luisa Chiapparini; Chiara Pantaleoni; Federica Natacci; Gaetano Finocchiaro; Veronica Saletti
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

6.  Clinical Characteristics and Mutation Spectrum of Neurofibromatosis Type 1 in 27 Turkish Families.

Authors:  Shahrashoub Sharifi; Tuğba Kalaycı; Şükrü Palanduz; Şükrü Öztürk; Kıvanç Cefle
Journal:  Balkan Med J       Date:  2021-11       Impact factor: 2.021

7.  Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study.

Authors:  Claire Forde; Emma Burkitt-Wright; Peter D Turnpenny; Eric Haan; John Ealing; Sahar Mansour; Muriel Holder; Nayana Lahiri; Abhijit Dixit; Annie Procter; Laurence Pacot; Dominique Vidaud; Yline Capri; Marion Gerard; Hélène Dollfus; Elise Schaefer; Chloé Quelin; Sabine Sigaudy; Tiffany Busa; Gabriella Vera; Lena Damaj; Ludwine Messiaen; David A Stevenson; Peter Davies; Sheila Palmer-Smith; Alison Callaway; Pierre Wolkenstein; Eric Pasmant; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2021-12-13       Impact factor: 4.246

8.  Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis.

Authors:  Emma Mm Burkitt Wright; Emma Sach; Saba Sharif; Oliver Quarrell; Thomas Carroll; Richard W Whitehouse; Meena Upadhyaya; Susan M Huson; D Gareth R Evans
Journal:  J Med Genet       Date:  2013-06-28       Impact factor: 6.318

9.  Patterns of Novel Alleles and Genotype/Phenotype Correlations Resulting from the Analysis of 108 Previously Undetected Mutations in Patients Affected by Neurofibromatosis Type I.

Authors:  Francesco Bonatti; Alessia Adorni; Annalisa Matichecchia; Paola Mozzoni; Vera Uliana; Francesco Pisani; Livia Garavelli; Claudio Graziano; Maria Gnoli; Diana Carli; Stefania Bigoni; Elena Boschi; Davide Martorana; Antonio Percesepe
Journal:  Int J Mol Sci       Date:  2017-09-29       Impact factor: 5.923

Review 10.  Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts.

Authors:  V Dunnett-Kane; E Burkitt-Wright; F H Blackhall; A Malliri; D G Evans; C R Lindsay
Journal:  Ann Oncol       Date:  2020-03-30       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.